These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20663804)

  • 1. Restoring circadian rhythms: a new way to successfully manage depression.
    Gorwood P
    J Psychopharmacol; 2010 Aug; 24(2 Suppl):15-9. PubMed ID: 20663804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission.
    Llorca PM
    J Psychopharmacol; 2010 Aug; 24(2 Suppl):21-6. PubMed ID: 20663805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agomelatine as chronopsychopharmaceutics restoring circadian rhythms and enhancing resilience to stress: a wishfull thinking or an innovative strategy for superior management of depression?
    Jakovljević M
    Psychiatr Danub; 2011 Mar; 23(1):2-9. PubMed ID: 21448091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing circadian rhythm disturbances in depressed patients.
    Lam RW
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):13-8. PubMed ID: 18753278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of early symptom relief in antidepressant treatment: focus on agomelatine.
    Lam RW
    J Psychopharmacol; 2010 Aug; 24(2 Suppl):27-30. PubMed ID: 20663806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine: innovative pharmacological approach in depression.
    Popoli M
    CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical discovery and development of agomelatine for the treatment of depression.
    Konstantakopoulos G; Dimitrakopoulos S; Michalopoulou PG
    Expert Opin Drug Discov; 2020 Oct; 15(10):1121-1132. PubMed ID: 32568567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating each and every depressed patient.
    Kennedy SH
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agomelatine: a narrative review.
    Demyttenaere K
    Eur Neuropsychopharmacol; 2011 Sep; 21 Suppl 4():S703-9. PubMed ID: 21835598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agomelatine: efficacy at each phase of antidepressant treatment.
    Kennedy SH
    CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerance profile of agomelatine and practical use in depressed patients.
    Rouillon F
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S31-5. PubMed ID: 16436938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agomelatine, an innovative pharmacological response to unmet needs.
    Le Strat Y; Gorwood P
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
    de Bodinat C; Guardiola-Lemaitre B; Mocaër E; Renard P; Muñoz C; Millan MJ
    Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Agomelatine: the first "melatoninergic" antidepressant].
    Bánki MC
    Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism, efficacy, and tolerability profile of agomelatine.
    MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agomelatine, a melatonin agonist with antidepressant properties.
    Dubovsky SL; Warren C
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.
    Kennedy SH; Rizvi SJ
    CNS Drugs; 2010 Jun; 24(6):479-99. PubMed ID: 20192279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical studies on the efficacy of agomelatine on depressive symptoms.
    Goodwin GM
    CNS Drugs; 2009; 23 Suppl 2():35-9. PubMed ID: 19708724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.